Sierra Oncology Reports First Quarter 2022 Results

SAN MATEO, Calif--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the first quarter ended March 31, 2022. “By entering into a merger agreement with GSK, we are...

Click to view original post